Seeking Alpha

Mylan gets a boost from the FDA's new guidelines for generic versions of Advair

  • Mylan (MYL +4.6%) hits another fresh high as the FDA's guidance regarding generic versions of Glaxo's (GSK) Advair strikes optimism that the generic-drug maker will one day get clearance to sell its own soon.
  • Up to now, no generic competitor to Advair has emerged because it's been unclear what would be required by regulators in order to win approval.
  • The FDA’s new guidelines now make it possible for Advair rivals to hit the market by 2016 or 2017.
  • MYL is considered one of the most viable companies to develop an Advair competitor.
Comments (1)
  • Up another 52% in the next 52 weeks for (MYL)?;c=
    10 Sep 2013, 09:00 PM Reply Like
DJIA (DIA) S&P 500 (SPY)